Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.

Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F Jr, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS.

J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.

PMID:
30025829
2.

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC.

Diabetes. 2018 Aug;67(8):1471-1480. doi: 10.2337/dbi18-0002. Epub 2018 Jun 24. Review.

3.

Implications of the EMPA-REG Trial for Clinical Care and Research.

Stamatouli AM, Inzucchi SE.

Curr Diab Rep. 2016 Dec;16(12):131. Review.

PMID:
27812962

Supplemental Content

Loading ...
Support Center